CSF3 and graft versus host disease: The mechanism for this is thought to be a combination of the effects of G-CSF priming of donor cells, in maintaining T cell hyporesponsiveness and encouraging the development of tolerant Th2 cells, as well as the in vivo effects of GVHD prophylaxis and ATG in the conditioning.